Company Filing History:
2 out of 1,933 
2 out of 547 
Years Active: 2022-2024
Title: John Koren: Advancing Neurodegenerative Disease Research through Innovation
Introduction
John Koren, an inventive mind based in Tampa, FL, has made significant contributions to the field of neurodegenerative disease research. Holding two patents, Koren focuses on developing methods to combat tauopathies, which are associated with the aggregation of tau proteins in neurodegenerative diseases.
Latest Patents
Koren's latest patents include innovative compounds and methods aimed at inhibiting Aha1, an essential factor in tau protein aggregation. His research highlights how the Aha1 inhibitor may effectively reduce the interaction between Aha1 and Hsp90, potentially mitigating the aggregation of tau proteins. Notable compounds in his findings include KU-177, KU-174, and KU-308, all of which could play a crucial role in addressing the challenges posed by tauopathies.
Career Highlights
Throughout his career, Koren has worked with prominent institutions, including the University of South Florida and the University of Kansas. His dedication to research in the biological sciences has facilitated advancements in understanding neurodegenerative processes and finding therapeutic targets.
Collaborations
In his journey, John Koren has collaborated with esteemed colleagues such as Chad Dickey and Lindsey Shelton. These partnerships underscore the collective effort required in research fields aimed at tackling complex medical conditions.
Conclusion
John Koren's innovative work exemplifies the critical intersection of research and practical application in combating neurodegenerative diseases. With his notable patents and collaborations, he continues to pave the way for future research and therapeutic developments in the realm of tauopathies.